Desidustat in the Treatment of Chemotherapy Induced Anemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anemia of Chronic Kidney Disease
- Chemotherapy Effect
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 125 years
- Gender
- Both males and females
Description
A total of up to approximately 24 patients will be enrolled to receive Desidustat in an open-label manner. The study is divided into three cohorts as given below: Cohort I: Single-dose 100 mg Cohort II: Single-dose 150 mg Cohort III: Single-dose 200 mg Note:- After evaluation of PK data of 100 mg do...
A total of up to approximately 24 patients will be enrolled to receive Desidustat in an open-label manner. The study is divided into three cohorts as given below: Cohort I: Single-dose 100 mg Cohort II: Single-dose 150 mg Cohort III: Single-dose 200 mg Note:- After evaluation of PK data of 100 mg dose cohort, next cohort with higher dose will be decided. Maximum dose of Desidustat will not be exceeded than 200 mg. First cohort will be given 100 mg single dose of Desidustat. On completion of safety and PK evaluation of first cohort,the next cohort with escalated single dose (150 mg) of Desidustat will be initiated. Similar way third cohort with 200 mg single dose will be initiated after safety evaluation of 150 mg cohort data.
Tracking Information
- NCT #
- NCT04667533
- Collaborators
- Not Provided
- Investigators
- Study Chair: Dr Deven Parmar, MD Cadila Healthcare Ltd.
Get Well Soon